• Skip to main content
  • Skip to header right navigation
  • Skip to site footer
CCAIM

CCAIM

Novel AI to transform healthcare

  • Home
  • About
    • Our Aims
    • ISAB Report
  • People
    • Leadership
    • Faculty
    • Associate Faculty
    • Joint Steering Committee
    • Independent Scientific Advisory Board
    • Staff
    • Our students
    • Affiliated clinical PhD Students
    • Visitors
  • Research
    • Papers
    • Breakthroughs
    • Software
      • AutoPrognosis
      • HyperImpute
      • Interpretability Suite
      • Synthcity
      • TemporAI
    • Demonstrators
    • Research Update: COVID-19
    • Blog
  • News
    • Latest News
    • COVID-19 News
  • Events
    • Seminar Series
    • WeCREATE
    • Inaugural Event
    • AI Clinic 2023
    • AI Clinic 2022
  • Summer School
    • Summer School 2023
      • Participate
      • Program
      • Topics
      • Industry
      • FAQ
    • Summer School 2022
  • Get involved
    • PhD Programmes
    • Clinical PhD Position
    • Partners
    • Connect

Next-generation Clinical Trials

We’re investigating how to optimise patient recruitment for enrolment in clinical trials and how to conduct more efficient, responsive trials.

PAPERS
BREAKTHROUGHS

Our work is informing the next generation of adaptive clinical trials, including determining sequential recruitment of patients, arriving at effective drug dosages and much more.

To compare the effectiveness of a new treatment with an existing treatment or a placebo, randomised controlled trials (RCTs) are considered the gold standard. The problem is that such clinical trials are often slow, costly and lack flexibility. In addition, as a result of insufficient analytical power, these trials may fail to uncover specific sub-populations of patients for which a treatment would be most effective.

What’s more, conclusions drawn from RCTs are typically valid only for the types of patients recruited for that RCT. This is an especially significant problem in the case of COVID-19, for example, as elderly patients and patients with comorbidities, who are known to be at higher risk, are typically excluded from RCTs.

Recent work on improving the design of adaptive clinical trials, by members of CCAIM and others, has revealed that the efficiency and effectiveness of many aspects of clinical trials can be significantly boosted through the application of machine learning. Here are just a few examples.

Adaptive, dynamic design

What makes ML-enhanced clinical trials so desirable? While traditional RCTs simply allocate patients to treatment and control groups through uniform randomisation, this procedure can be far from optimal in terms of learning. ML-enhanced trials can recruit patients in cohorts rather than all at once, allowing the treatment effects on each cohort to be observed before deciding who in the subsequent cohort should be assigned to the treatment or control groups, speeding up learning.

With AI/ML technology analysing a wide range of trial-participant data, and their responses to treatment, it becomes possible to identify sub-populations of patients with particular characteristics that are responding in different ways to the treatment. Such techniques have been shown to significantly reduce error and achieve a prescribed level of confidence in their result while requiring fewer patients – a double win.

Another example of where ML techniques can boost adaptive clinical trials is in Phase I dose-finding trials. These trials are increasingly challenging as the relationship between efficacy and toxicity of new compounds or combinations becomes more complex. Despite this, most commonly used methods in practice focus on identifying a Maximum Tolerated Dose (MTD) by learning only from toxicity events. ML techniques can outperform state-of-the-art clinical trial designs by finding the optimal dose with higher success rate and fewer patients.

Sidebar

Unable to load Tweets

Follow

Recent Posts

  • Prof Mihaela van der Schaar joining panel on oncology at ASCO2023
  • Learning Representations without Compositional Assumptions
  • Revolutionising Pharmacological Predictions: How Synthetic Model Combination (SMC) Could Change the Game for Drug Development
  • CCAIM at ICML 2023: 12 papers from our faculty
  • Staff

Navigation

Home

News

About

University of Cambridge

  • University A-Z
  • Contact the University
  • Accessibility
  • Data Protection
  • Terms and conditions

Newsletter

Sign-up for updates on our research.

Follow us

  • Twitter
  • LinkedIn
  • YouTube

Copyright © 2023 CCAIM

Return to top

We are using cookies to give you the best experience on our website.

You can find out more about which cookies we are using or switch them off in settings.

CCAIM
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.

Strictly Necessary Cookies

Strictly Necessary Cookie should be enabled at all times so that we can save your preferences for cookie settings.

If you disable this cookie, we will not be able to save your preferences. This means that every time you visit this website you will need to enable or disable cookies again.

3rd Party Cookies

This website uses Google Analytics to collect anonymous information such as the number of visitors to the site, and the most popular pages.

Keeping this cookie enabled helps us to improve our website.

Please enable Strictly Necessary Cookies first so that we can save your preferences!